Presentations

December 8, 2019
61st ASH Annual Meeting & Exposition
6:00pm-8:00pm ET, Orlando, FL

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “Preclinical Characterization of PRGN-3006 UltraCAR-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer.” (Abstract #2660)

December 5, 2019
World Vaccine & Immunotherapy Congress
9:10am PT, San Francisco, CA

Helen Sabzevari, PhD, President of Precigen, will present the keynote “Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors.”

January 9, 2019
37th Annual JP Morgan Healthcare Conference
11:30am PT, San Francisco, CA US

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, and Helen Sabzevari, PhD, President of Precigen, presented an overview of Precigen at the 37th annual JP Morgan Healthcare Conference.

 


January 7, 2019
Precigen Company Update during 37th Annual JP Morgan Healthcare Conference
3:00pm PT, San Francisco, CA US

Helen Sabzevari, PhD, President of Precigen, provided an overview of the company, the long-term vision for the company, and an introduction and overview of current preclinical and clinical programs in immuno-oncology, autoimmune disorders and infectious diseases.

 


December 26, 2018
Precigen Business Update
8:30am ET, Germantown, MD US

Helen Sabzevari, PhD, President of Precigen, provided business updates, including an overview of Precigen’s recent transition from an exclusive channel collaboration model to an agile R&D engine for greater focus, full developmental control and acceleration of its core programs and an overview of the recently announced FDA clearance for the Investigational New Drug (IND) application for the first-in-class PRGN-3006 UltraCAR-T™ therapy for treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS).

SUBSCRIBE TO OUR NEWS ALERTS

Receive email announcements and news alerts about Precigen by signing up with the form below.